Effect of chromogranin A N-terminal fragment vasostatin-1 nano-carrier transfection on abdominal aortic aneurysm formation

Figures & data

Figure 1. Schematic diagram for structure of pCDNA3.1-VS-1 NP

Figure 2. Preparation of carrying pCDNA3.1-VS-1 NP

Figure 3. AMPK/mTOR SP

Figure 4. Amplification of VS-1 DNA with PCR

Note: each lane represented the VS-1 DNA fragment amplified from different primers. Lane 1 ~ 6 represented the primer 1, 2, 3, 1 + 2, 2 + 3, and 1 + 2 + 3, respectively.

Figure 5. Identification results after digestion of pCDNA3.1-VS-1 NP

Figure 6. DNA sequencing of pCDNA3.1-VS-1 NP

Figure 7. Microscopic morphologic surface of VS-1 NP

Note: ×15,000, and 20 kV.

Figure 8. Curve for particle size distribution

Figure 9. Cumulative release curve

Figure 10. Incidence of AAA and DE for rats in each group

Note: (10 ×), * indicated P < 0.05 compared with sham; # indicated P < 0.05 compared with AAA.

Figure 11. Comparison on HE staining results of AA for rats in each group (100 ×)

Figure 12. Comparison on immunohistochemical results of AMPK of rats in each group

Note: (10 ×), * indicated P < 0.05 contrasted with Sham; # indicated P < 0.05 compared to AAA.

Figure 13. Comparison on immunohistochemical results of mTOR of rats in each group

Note: (100 ×), * indicated P < 0.05 contrasting with Sham; # indicated P < 0.05 in comparison to AAA.

Figure 14. Comparison on p-AMPK PE in AA in each group

Note: * indicated P < 0.05 contrasted with Sham; # indicated P < 0.05 compared to AAA.

Figure 15. P-mTOR PE in AA in each group

Note: * indicated P < 0.05 compared to sham; # indicated P < 0.05 compared with AAA.

Figure 16. Correlation between p-AMPK PE and ED of rats in all groups

Figure 17. Correlation between p-mTOR PE and ED of rats in all groups

Data availability statement

All data, models, and code generated or used during the study appear in the submitte.